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Previewsthe effects of FTO overexpression on
obesity are mediated via the brain or other
tissues. Deletion of fto in the brain recapit-
ulates the reduced bodyweight of fto nulls,
indicating that central mechanisms are
likely to play a major role (Gao et al., 2010).
Finally, studies of the FTO association
signal have taught us that understanding
the biology underlying these genetic
associations can be a complex and chal-
lenging task. As more common variants
and, indeed, rare variants emerge from
hypothesis-free genetic approaches,
collaborative work across disciplines will
be needed to link these genes to physio-
logical and pathophysiological processes
and thus to explore their utility as potential
molecular targets for intervention in8 Cell Metabolism 13, January 5, 2011 ª2011patients with obesity and associated
metabolic diseases.REFERENCES
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Howcellularmetabolism regulates stem cell function is poorly understood but is an emerging field of study. In
a recent issue of Nature, three independent groups demonstrate that LKB1 promotes hematopoietic stem
cell (HSC) quiescence and metabolic homeostasis. Surprisingly, these effects on HSCs occur independently
of AMPK/mTOR and FoxO signaling.LKB1 is a tumor suppressor that is inacti-
vated in the Peutz-Jeghers familial cancer
syndrome. Best characterized as a serine/
threonine kinase acting upstream of
the adenine monophosphate-activated
protein kinase (AMPK) and mammalian
target of rapamycin (mTOR) pathways,
LKB1 is currently viewed as a master
regulator of cellular metabolism that
restricts cell growth under energetically
unfavorable conditions (Shackelford and
Shaw, 2009). Increased cellular AMP/
ATP ratios result in enhanced AMPK
phosphorylation and activation by LKB1.Activated AMPK in turn phosphory-
lates the tuberous sclerosis complex
(TSC), which inhibits mTOR complex 1
(mTORC1), resulting in reduced mRNA
translation and cell growth. LKB1 also
modulates metabolism via other AMPK
targets (such as the FoxO transcription
factors) or additional substrates, like the
14 AMPK-related kinases. Although the
role of LKB1 in regulating metabolic
activity in cancer is well established,
its impact on stem cells has yet to be
fully explored. Accordingly, three recent
reports in Nature (Gan et al., 2010; Guru-murthy et al., 2010; Nakada et al., 2010)
demonstrate that LKB1 plays a critical
role in hematopoietic stem cell (HSC)
quiescence.
The hematopoietic system functions to
replenish multilineage blood cells from
early embryonic development throughout
adulthood. Multipotent HSCs give rise to
all mature blood lineages and must main-
tain a delicate balance between quies-
cence, self-renewal, and differentiation.
Complex regulatory mechanisms, both
cell intrinsic and cell extrinsic, modulate
this balance and have profound influence
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Figure 1. Role of LKB1 in Hematopoietic Stem Cells
LKB1 promotes HSC quiescence and maintenance through regulating proliferation, metabolism, and cell survival in an AMPK-, mTORC1-, and FoxO-indepen-
dent mechanism. The LKB1 target that mediates HSC function is unknown and could be one of the 14 known AMPK-related kinases. AMPK, mTORC1, and FoxO
are regulated by LKB1 in HSCs but do not contribute to HSC quiescence.
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Previewsover HSC behavior. Cellular stress also
contributes, as responses to nutrient
deprivation, metabolic and/or oxidative
imbalances, and hypoxia all impact
stem cell quiescence, differentiation, and
survival. Interestingly, recent reports
demonstrate that HSCs (Parmar et al.,
2007) and hippocampal NSCs (Mazumdar
et al., 2010) stain positive for the hypoxia
marker pimonidazole, indicating that
some stem cell populations occupy
poorly oxygenated microenvironments.
Consistent with a hypoxic HSC niche,
HSCs utilize glycolysis instead of mito-
chondrial oxidative phosphorylation for
energy production (Simsek et al.,
2010). This hypoxic influence on HSC
metabolism is through hypoxia-inducible
factor-1a (HIF-1a), which also promotes
HSC quiescence by regulating p16Ink4a
and p19Arf (Takubo et al., 2010). In
NSCs, HIF-1a enhances Wnt/b-catenin
signaling, supporting their proliferation,
survival, and integration within the
hippocampal circuitry (Mazumdar et al.,
2010). Given the metabolic demands of
a low-O2 microenvironment, it is not
surprising that the HIF and mTOR (Yilmaz
et al., 2006) stress-response pathways
regulate HSC quiescence. However, the
full complement of metabolic pathways
regulating this aspect of HSC biology
remains undefined. These three indepen-
dent reports investigate the role of themetabolic sensor LKB1 in HSCs and
reveal that it is critical for HSC function
(Gan et al., 2010; Gurumurthy et al.,
2010; Nakada et al., 2010).
To probe metabolic regulation of HSC
behavior, Lkb1 was conditionally deleted
in the mouse hematopoietic system using
either Rosa26-creERt2 or Mx1-Cre. Upon
LKB1 ablation, all three studies observed
an immediate loss of HSC quiescence
and increased HSC/multipotent progen-
itor cell proliferation. Interestingly, this
effect was not observed in mature hema-
topoietic cells, indicating a unique role for
LKB1 in stem cells. The overall increase in
progenitor numbers, however, was tran-
sient, followed by a progressive depletion
of HSCs and eventual pancytopenia.
The effect of Lkb1 deletion proved to
be cell autonomous, as mutant HSCs
failed to rescue lethally irradiated recipi-
ents and were outcompeted by Lkb1-
replete HSCs in competitive reconstitu-
tion assays.
Because LKB1 is best known as a
regulator of AMPK, mTORC1, and FoxO,
these pathways were examined to
mechanistically explain the rapid depletion
of LKB1-deficient HSCs. Consistent with
previously established functions of LKB1,
mutant HSCs displayed a predictable loss
of AMPKa phosphorylation and increase
in phospho-S6 levels, demonstrating
decreased AMPK activity and increasedCell MetabolismmTORC1activity in theHSCcompartment.
Since enhanced mTORC1 activity results
in HSC depletion (Yilmaz et al., 2006), this
pathwaywasaprimecandidate tomediate
the HSC phenotype in Lkb1 mutants.
However, administration of rapamycin, an
mTORC1 inhibitor, failed to rescue HSC
depletion or BM reconstitution, although
phospho-S6 levels were reduced. FoxO-
deficient HSCs exhibit reduced survival
and function due to impaired reactive
oxygen species regulation; however,
administration of the antioxidant N-acetyl-
cysteine (NAC), also failed to rescue these
phenotypes in Lkb1 mutants, demon-
strating a FoxO-independent role for
LKB1. Decreased AMPK activity does not
account for the observed defects, as
administration of the AMPK activators
metformin (Gan et al., 2010) or A-769662
(Gurumurthy et al., 2010) failed to rescue
phenotypes exhibited by Lkb1 mutant
HSCs. Moreover, simultaneous deletion
of the AMPK catalytic subunits Ampka1
and Ampka2 did not phenocopy LKB1
deficiency (Nakada et al., 2010). Collec-
tively, these data demonstrate that LKB1
regulates HSC quiescence through an
AMPK-, mTORC1-, and FoxO-indepen-
dent mechanism.
With most known functions of LKB1
excluded, how does LKB1 regulate HSC
quiescence and survival? Transcriptome
analysis of Lkb1 mutant HSCs revealed13, January 5, 2011 ª2011 Elsevier Inc. 9
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Previewsenrichment for genes involved in the
PPARg metabolic pathway, with downre-
gulation of PPARg coactivators Pgc-1a
and Pgc-1b (Gan et al., 2010). Consistent
with PPARg’s role in mitochondrial
biogenesis and function, defects in mito-
chondrial number and function were
observed. Importantly, Ampka1/Ampka2
mutants also displayed these mitochon-
drial phenotypes, demonstrating that
LKB1 regulates mitochondria in an
AMPK-dependent manner. Gurumurthy
et al. took a different approach and
defined the metabolic profiles of mutant
HSCs that displayed elevated fatty acid
levels, suggesting LKB1 regulates addi-
tional aspects of cellular metabolism.
Nakada et al. examined proliferation of
mutant HSCs in vitro and found that
LKB1-deficient cells exhibited defects in
mitosis, characterized by supernumerary
centrosomes and aberrant mitotic spin-
dles. These cells became aneuploid and
underwent apoptosis in an AMPK-inde-
pendent manner (Nakada et al., 2010).
Interestingly, Ampka1/Ampka2 mutant
HSCs displayed metabolic dysfunction
but could fully reconstitute irradiated
recipients, suggesting that LKB1-medi-
ated regulation of mitosis and genome
stability accounts for HSC loss.10 Cell Metabolism 13, January 5, 2011 ª201These studies, summarized in Figure 1,
convincingly demonstrate a role for the
metabolic regulator LKB1 in HSC homeo-
stasis. An intriguing question that arises is
whether LKB1 plays a similar role in all
stem cell populations or is restricted to
stem cells that are under increased meta-
bolic stress. Comparing the role of LKB1
in stem cells within hypoxic niches to
those in well-oxygenated niches will be
particularly informative (e.g., NSCs of the
subventricular zone of the adult brain
[Shen et al., 2008]). Additionally, the
specific effectors of LKB1 in HSCs have
yet to be defined. Whether LKB1 regu-
lates HSC quiescence through the 14
other AMPK-related kinases or through
another mechanism remains an important
area of investigation. In summary, these
exciting studies reveal that LKB1 is
an essential stem cell factor that pro-
motes HSC quiescence and maintenance
through a variety of mechanisms yet to be
elucidated.REFERENCES
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